Scarica l'app Stockscreener
56.29
0.16%
-0.09
Pre-mercato:
56.50
0.21
+0.37%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$56.38
Aprire:
$56
Volume 24 ore:
10.50M
Relative Volume:
1.08
Capitalizzazione di mercato:
$114.17B
Reddito:
$47.44B
Utile/perdita netta:
$-7.26B
Rapporto P/E:
-15.68
EPS:
-3.59
Flusso di cassa netto:
$13.80B
1 W Prestazione:
+0.82%
1M Prestazione:
-2.36%
6M Prestazione:
+30.45%
1 anno Prestazione:
+12.63%
Intervallo 1D:
$55.55
$56.62
Intervallo di 1 settimana:
$54.81
$56.74
Portata 52W:
$39.35
$61.08
Bristol Myers Squibb Co Stock (BMY) Company Profile
Nome
Bristol Myers Squibb Co
Settore
Industria
Telefono
(609) 252-4621
Indirizzo
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Confronta BMY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
56.29 | 114.17B | 47.44B | -7.26B | 13.80B | -3.59 |
|
LLY
Lilly Eli Co
|
725.72 | 689.73B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
78.69 | 349.44B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
147.03 | 344.63B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
171.56 | 303.17B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
97.92 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-13 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Downgrade | Citigroup | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-07-29 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Downgrade | Societe Generale | Buy → Hold |
| 2024-02-06 | Downgrade | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-07-10 | Iniziato | SVB Securities | Market Perform |
| 2023-06-28 | Iniziato | Daiwa Securities | Outperform |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-01-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Iniziato | Credit Suisse | Neutral |
| 2022-10-10 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-09-14 | Downgrade | Berenberg | Buy → Hold |
| 2022-06-03 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Underweight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-01 | Downgrade | Argus | Buy → Hold |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Aggiornamento | Truist | Hold → Buy |
| 2020-11-16 | Aggiornamento | Societe Generale | Hold → Buy |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-11-06 | Downgrade | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-07-28 | Iniziato | Raymond James | Outperform |
| 2020-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-06 | Ripresa | Citigroup | Buy |
| 2019-12-13 | Aggiornamento | Argus | Hold → Buy |
| 2019-11-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-08-14 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-05-20 | Downgrade | Argus | Buy → Hold |
| 2019-05-03 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Ripresa | JP Morgan | Overweight |
| 2019-01-15 | Aggiornamento | Societe Generale | Sell → Buy |
| 2018-10-22 | Downgrade | Citigroup | Buy → Neutral |
Mostra tutto
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
M.E. Allison & CO. Inc. Purchases New Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb Company (BMY): A Bull Case Theory - Yahoo Finance UK
HB Wealth Management LLC Raises Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Why Bristol-Myers Squibb (BMY) Is One of the Best Cheap Stocks to Buy for 2025? - Insider Monkey
Trust Co. of Vermont Has $2.55 Million Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Says New Schizophrenia Drug Off to Strong Start - MSN
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Copy of Jim and Mia Cassady Are Bringing Pickleball Centers to Delaware County #2 - BUCKSCO.Today
Bristol-Myers Squibb Company – Consensus ‘hold’ rating and 9.1% Upside Potential - DirectorsTalk Interviews
8,382 Shares in Bristol-Myers Squibb (NYSE:BMY) Acquired by Decker Retirement Planning Inc. - MarketBeat
Eagle Rock Investment Company LLC Lowers Stock Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
8,620 Shares in Bristol-Myers Squibb (NYSE:BMY) Acquired by Contravisory Investment Management Inc. - MarketBeat
Earnings Preview: What To Expect From Bristol-Myers Squibb's Report - Barchart
Cobenfy: Bristol Myers Squibb's Answer to Alzheimer's and SchizophreniaNews and Statistics - IndexBox, Inc.
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug - CNBC
Meyer Handelman Co. Decreases Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Radnor Capital Management LLC Has $4.57 Million Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Acropolis Investment Management LLC Has $1.92 Million Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Leerink Partnrs Analysts Lift Earnings Estimates for BMY - MarketBeat
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Bristol Myers Says New Schizophrenia Drug Off to Strong Start | Company Business News - Mint
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock - Yahoo Finance
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Wright Investors Service Inc. - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Stake Raised by Brookstone Capital Management - MarketBeat
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo (Dec. 27) - MSN
Bristol Myers Squibb CEO describes new drug for treating schizophrenia - NBC Philadelphia
Bristol-Myers Squibb (BMY) Releases New Investor Presentation - GuruFocus.com
Mid American Wealth Advisory Group Inc. Decreases Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Capital Investment Advisors LLC Has $14.02 Million Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Why Is Intra-Cellular Therapies Surging On Monday?Intra-Cellular Therapies (NASDAQ:ITCI), Johnson & Johnson (NYSE:JNJ) - Benzinga
Czech National Bank Raises Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors - The Manila Times
Bristol Myers Squibb licenses new CAR T therapy - Investing.com
Retinoblastoma Market Profiles: Segment Size, Growth, - openPR
The Bristol Myers Squibb Foundation - Bristol Myers Squibb
Hypercholesterolemia Treatment Market Top PlayersAbbVie, - openPR
West Oak Capital LLC Has $2.28 Million Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture? - Benzinga
Franklin Street Advisors Inc. NC Raises Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Abbvie to record $3.5 bln charge related to schizophrenia drug - Reuters
Bristol Myers Squibb (BMY) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference - Benzinga
8 Undervalued Stocks That Just Raised Dividends - Morningstar
How To Put $100 In Your Retirement Fund Each Month With Bristol-Myers Squibb Stock - Yahoo Finance
NUT Midline Carcinoma Treatment Market Research Report 2023-2024 & 2034: Market Forecast by Treatment, Route of Administration, and End-User Across 5 Regions and 17+ Countries - GlobeNewswire Inc.
International Assets Investment Management LLC Reduces Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Car T Cell Therapy Market Investment Opportunities: A Guide to 2031 | Bristol-Myers Squibb Company, Novartis - EIN News
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day - MarketWatch
114,649 Shares in Bristol-Myers Squibb (NYSE:BMY) Bought by InvesTrust - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Douglas Lane & Associates LLC - MarketBeat
Bristol Myers Squibb Co Azioni (BMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.21%
0.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):